glp-1 tachycardia Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices The Cardiovascular Biology of Glucagon-like

The GLP-1 landscape is experiencing a significant shift, with Canada leading the way

Its easy to become fixated on the very small and still-debated risk of a medication while ignoring the much larger and clear risks of foregoing treatment

It's only 215 calories and 20g protein, keeping me full and on track without feeling deprived

Data on hepatic fibrosis are limited or inconclusive, although some studies reported improvement in indices of fibrosis or prevention of fibrosis initiation or reduction of collagen deposition

According to Chicory's 2026 GLP-1 Survey of 1,000+ U.S

Learn about the risks of gastrointestinal adverse events.